Diaceutics PLC, a data analytics and implementation services company which services the global pharmaceutical industry, has announced the admission of its entire issued ordinary share capital, which comprises 69,583,077 ordinary shares (“Ordinary Shares”) to trading on the AIM market of the London Stock Exchange (“Admission”) on the, 21 March 2019. Dealings in the Ordinary Shares commenced at 8:00 a.m. under the ticker “DXRX” and ISIN GB00BJQTGV64.
The Company’s Admission Document is available from www.diaceutics.com
The Company has successfully raised £17 million gross (before expenses) through a placing of 22,368,427 new Ordinary Shares through its nominated adviser and broker, Cenkos Securities plc. In addition, 4,934,205 existing Ordinary Shares have been placed on behalf of existing shareholders.
Transaction highlights include:
- £17 million raised by the conditional placing of 22,368,427 new Ordinary Shares at a placing price of 76p
- The new Ordinary Shares represent 32.15 per cent. of the enlarged share capital on Admission
- Enlarged share capital on Admission of 69,583,077 Ordinary Shares
- £52.9 million market capitalisation on Admission at the placing price
- Cenkos Securities plc is Nominated Adviser and Broker
Peter Keeling, CEO of Diaceutics PLC, said: “We are very pleased with the level of interest generated from new institutional investors in support of our admission to trading on AIM. The move to AIM and the additional funding will allow us to continue our growth trajectory by developing our product and services offering which is focused on better testing and better treatment in the global pharmaceutical industry. The name Diaceutics reflects our activities at the intersection between diagnostics and pharmaceuticals, as does the ticker we chose, DXRX which uses DX, the industry short hand for a diagnostic and RX, the one for a prescription drug. We would like to thank our new and existing investors for their support, and the whole Diaceutics team for coming with us on this exciting journey.”